Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The companyâs patented DPPÂŽ technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. Coupled with Chembioâs extensive scientific expertise, its novel DPPÂŽ technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembioâs products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Source
No articles found.
Axcella is designing and developing AXA Candidates, compositions of endogenous met...
Axcella is designing and developing AXA Candida...
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...
Founded in November 2012, ObsEva is a clinical-...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
Global Cancer Technology (GCT) is an emerging medical technology company with nu...
Global Cancer Technology (GCT) is an emerging...
We are a leading, rapidly growing synthetic biology company that has developed a d...
We are a leading, rapidly growing synthetic bio...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.